• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Caverject
    / Pfizer


    Active Ingredient
    Alprostadil 10 mcg, 20 mcg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 X 10 mcg/vial

    not in the basket chart 22284 3009

    Vial

    1 X 20 mcg/vial

    not in the basket chart 9322 3010

    Related information


    Dosage

    This product is administered by direct intracavernosal injection. A ½-inch, 27- to 30-gauge needle is generally recommended. The dose should be individualized for each patient by careful titration under supervision by the physician. In clinical studies, patients were treated in doses ranging from 0.2 to 20 micrograms; however, since 99% of patients received doses of 20 micrograms or less, doses of greater than 20 micrograms are not recommended. In general, the lowest possible effective dose should always be employed. For full details see prescribing information.


    Indications

    Erectile dysfunction, adjunctive to diagnosis of erectile dysfunction.


    Contra-Indications

    This product should not be used in patients who have a known hypersensitivity to the drug or to other prostaglandins, or in patients who have conditions that might predispose them to priapism, such as sickle cell anemia or trait, multiple myeloma, or leukemia, or in patients with anatomical deformation of the penis, such as angulation, cavernosal fibrosis, or Peyronie’s disease. Patients with penile implants should not be treated with this product. This product should not be used in women or children and is not for use in newborns. This product should not be used in men for whom sexual activity is inadvisable or contraindicated.


    Special Precautions

    Priapism (erection lasting over 4 hours) is known to occur following intracavernosal administration of vasoactive substances, including this product. The patient should be instructed to immediately report to his physician any erection that persists for longer than 4 hours. Treatment of priapism should be according to established medical practice. Painful erection is more likely to occur in patients with anatomical deformations of the penis, such as angulation, phimosis, cavernosal fibrosis, Peyronie’s disease or plaques. Treatment should be discontinued in patients who develop penile angulation, cavernosal fibrosis, or Peyronie’s  disease.
    Patients on anticoagulants such as warfarin or heparin may have increased propensity for bleeding after intracavernosal injection. Underlying treatable medical causes of erectile dysfunction should be diagnosed prior to initiation of therapy. Use of this product offers no protection from the transmission of sexually transmitted diseases. Individuals who use this product should be counselled about the protective measures that are necessary to guard against the spread of sexually transmitted diseases, including the human immunodeficiency virus (HIV).


    Side Effects

    The following adverse reactions information was obtained from clinical studies sponsored by Upjohn involving 1712 patients treated with this product. The most frequent adverse reaction after intracavernosal injection is penile pain. In studies, 34% of the patients reported penile pain during erection at least once, however, this event was associated with only 11% of the administered injections. In the majority of the cases, burning sensation or tension in the penis was rated mild or moderate in intensity. Three percent of patients discontinued treatment because of penile pain. Hematoma at the site of injection, which is related to the injection technique rather than to the effects of alprostadil, occurs in 3% of patients. The frequency of prolonged erection (defined as an erection that lasts for 4 hours) was 2%. The frequency of priapism (defined as an erection that lasts 4 hours or longer) was 0.5%. In the majority of cases, spontaneous detumescence occurred. The following local adverse reactions occurred in 1.0-1.5% of patients: injection site ecchymosis, penile rash, penile edema, and penile fibrosis. The following local adverse reactions were reported by fewer than 1% of patients: balanitis, injection site hemorrhage, injection site inflammation, injection site itching, injection site swelling, urethral bleeding, and penile warmth, numbness, yeast infection, irritation, sensitivity, phimosis, pruritus, erythema, venous leak, painful erection, and abnormal ejaculation. In terms of systemic events, the following were reported for fewer than 1% of patients in clinical studies, and were judged to be possibly related to use: testicular pain, testicular swelling, scrotal erythema, pain or tightness, urinary frequency, urinary urgency, impaired urination, hypotension, vasodilatation, hypertension, supraventricular extrasystole, peripheral vascular disorder, dizziness, hypesthesia, buttock weakness, localized pain (buttocks pain, leg pain, genital pain, abdominal pain), headache, pelvic pain, back pain, flu syndrome, cardiac arrhythmias, shock and collapse. Hemodynamic changes, manifested as decreases in blood pressure and increases in pulse rate, were observed during clinical studies, principally at doses above 20 micrograms and above 30 micrograms, respectively, and appeared to be dose-dependent. Only three patients (0.2%) discontinued the treatment because of symptomatic hypotension. This product had no clinically important effect on serum or urine laboratory tests.


    Drug interactions

    Warfarin, heparin. No known interactions. This product is not intended for coadministration with any other agent for the treatment of erectile dysfunction.


    Pregnancy and Lactation

    Not applicable.


    Overdose

    In man, prolonged erection and/or priapism are known to occur following intracavernosal administration of vasoactive substances, including alprostadil. The treatment of priapism may include different approaches such as aspiration, intracavernosal injection of sympathomimetic amines or surgery. Patients should be instructed to report to a physician any erection lasting for a prolonged time period, such as 4 hours or longer.


    Manufacturer
    PFIZER Manufacturing Belgium NV, Belgium
    CLOSE